Citius Oncology

Citius Oncology Equity

The The Equity of Citius Oncology (CTOR) as of Nov 21, 2026 is 44.87 M USD. In the previous year, The Equity was 46.14 M USD — a change of -2.76% (lower).

Equity

44.87 MUSD

YoY

-2.76%

Last updated:

In 2025, Citius Oncology's equity was 44.87 M USD, a -2.76% increase from the 46.14 M USD equity in the previous year.

The Citius Oncology Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2022
36.27 M USD
Jan 1, 2023
25.54 M USD
Jan 1, 2024
46.14 M USD
Jan 1, 2025
44.87 M USD
The Citius Oncology Equity history
YEAREquityYoY
44.87 MUSD-2.76%
46.14 MUSD+80.69%
25.54 MUSD-29.59%
36.27 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Citius Oncology Stock analysis

What does Citius Oncology do? Citius Oncology, Inc. develops and commercializes targeted oncology therapies, with its lead product candidate LYMPHIR for treating persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein that targets IL-2 receptors on cancer cells, inhibiting protein synthesis and causing cell death. The company focuses on relapsed or refractory cutaneous T-cell lymphoma (CTCL) patients after at least one prior systemic therapy, with the product indicated for Stage I-III disease. Citius Oncology, Inc. is a pharmaceutical company engaged in developing and commercializing targeted oncology therapies, with LYMPHIR as its primary product. The company's lead candidate targets CTCL, a rare non-Hodgkin lymphoma, and is designed for patients who have failed prior systemic treatments. The therapeutic mechanism involves binding to IL-2 receptors, delivering diphtheria toxin fragments to inhibit protein synthesis within cancer cells. The company's commercial strategy centers on LYMPHIR, which is positioned for relapsed or refractory CTCL patients requiring additional treatment options. LYMPHIR's mechanism of action specifically targets IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis. This targeted approach differentiates the product in the oncology therapy market for rare lymphoma subtypes. Citius Oncology is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Citius Oncology's Equity

Citius Oncology's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Citius Oncology's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Citius Oncology's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Citius Oncology's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Citius Oncology’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Citius Oncology stock

The Equity of Citius Oncology is 44.87 M USD in 2025.

The Equity of Citius Oncology changed from 46.14 M USD to 44.87 M USD, representing a -2.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Citius Oncology since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Citius Oncology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Citius Oncology

All Key Metrics — Citius Oncology